Antiviral Mechanisms of Action

1. What This Mechanism of Action Entails

Antiviral mechanisms of action include direct inhibition of viral replication, enhancement of the immune response, or modulation of inflammatory processes. In the laboratory, cellular models are often used to analyse the interaction between virus and host cell, for example by measuring viral load or cell damage. Animal studies allow the observation of systemic effects, such as those on organs or immune cells. In humans, clinical endpoints such as duration of symptoms, hospitalisation rate, or viral load are the primary focus. Some mechanisms, such as binding to viral proteins, can be readily demonstrated in the laboratory, whereas complex immune modulations are more difficult to quantify.

Measurability in humans depends on the availability of valid biomarkers and clinical endpoints. Direct antiviral effects (e.g., inhibition of viral enzymes) are easier to capture in the laboratory, while systemic effects (e.g., anti-inflammatory action) often require indirect markers. Controlled human studies are resource-intensive and require clear hypotheses to demonstrate efficacy and safety. Substances with a broad spectrum of action, such as vitamin D or zinc, have therefore been studied more frequently than those with specific but difficult-to-measure mechanisms.

2. Which Substances Share This Mechanism

All substances in the database for which this mechanism of action is described—ranked by the extent of human testing. The numbers represent studies per type of investigation.

3. How Robust the Evidence Is

Substances such as vitamin D, zinc, probiotics, and turmeric/curcumin are supported by numerous controlled human studies, with vitamin D and zinc demonstrating the highest level of evidence. Other substances, such as humic acid complexes, beta-glucans, or quercetin, show promising laboratory and animal study data but have so far been scarcely validated in clinical trials. Chronic inflammation and the gut microbiome are well-documented as overarching factors; however, their targeted modulation often remains non-specific. Some substances, such as ginger or berberine, are almost entirely absent from controlled human studies.

Many substances share similar mechanisms of action, such as the inhibition of viral replication or the modulation of inflammatory mediators. For example, both humic acid complexes and quercetin act in vitro through direct binding to viral proteins, whereas vitamin D and omega-3 fatty acids exert primarily immunomodulatory effects. While extrapolation from laboratory findings to humans is plausible, it is not always applicable, as factors like bioavailability, dosage, or interactions with other elements in the organism may vary. Substances with a broad spectrum of activity (e.g., adaptogens) may act synergistically but have rarely been studied in combination.

4. Key Human Studies

• 1 "Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients (2020) — Vitamin D"
• 2 Vitamin D receptor stimulation to reduce acute respiratory distress syndrome (ARDS) in patients with coronavirus SARS-CoV-2 infections: Revised Ms SBM (2020) — Vitamin D
• 3 Treatment With 25-Hydroxyvitamin D₃ (Calcifediol) Is Associated With a Reduction in the Blood Neutrophil-to-Lymphocyte Ratio Marker of Disease (2021) — Vitamin D
• 4 Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection (2021) — Zinc
• 5 Treatment of SARS-CoV-2 with high dose oral zinc salts: A report on four patients (2020) — Zinc
• 6 Low Zinc Levels at Admission Associates with Poor Clinical Outcomes in SARS-CoV-2 Infection (2021) — Zinc
• 7 Stimulating the Resolution of Inflammation Through Omega-3 Polyunsaturated Fatty Acids in COVID-19: Rationale for the <i>COVID-Omega-F</i> Trial (2020) — Chronic inflammation
• 8 Effects of Semaglutide on Cognitive Function in People With HIV: A Randomised, Controlled Trial (2026) — Chronic inflammation
• 9 ARACOV-02. Specialised nutritional intervention and telerehabilitation in patients with long COVID: Protocol of a randomised controlled trial (2025) — Chronic inflammation
• 10 A randomised controlled trial to investigate the influence of an exercise intervention on brain integrity and gut microbiome structure in individuals with (2026) — Gut microbiome
• 11 Mouthrinses differentially rewire salivary virus-microbiome interaction dynamics in COVID-19 patients: A randomised controlled trial (2026) — Gut microbiome
• 12 Pharmacological and non-pharmacological management of long COVID (2026) — Gut microbiome
• 13 The influence of prebiotic or probiotic supplementation on antibody titres after influenza vaccination: a systematic review and meta-analysis of randomised controlled trials (2018) — Probiotics
• 14 Probiotics and prebiotics: potential prevention and therapeutic target for nutritional management of COVID-19? (2023) — Probiotics
• 15 Testing the regulatory framework in South Africa – a single-blind randomised pilot trial of commercial probiotic supplementation alongside standard therapy (2020) — Probiotics
• 16 A standardised ashwagandha root extract alleviates stress, anxiety, and improves quality of life in healthy adults by modulating stress hormones: results of a randomised, double-blind, placebo-controlled trial (2023) — Adaptogens
• 17 Efficacy of adaptogens in patients with long COVID-19: a randomised, quadruple-blind, placebo-controlled trial (2022) — Adaptogens
• 18 <i>Withania somnifera</i> (L.) Dunal as add-on therapy for patients with COPD: a randomised, placebo-controlled, double-blind study (2022) — Adaptogens
• 19 Oral curcumin with piperine as adjuvant therapy for the treatment of COVID-19: a randomised clinical trial (2021) — Turmeric and curcumin
• 20 Efficacy of an oral nano-curcumin formulation in the management of mild to moderate outpatient COVID-19: a randomised, triple-blind, placebo-controlled clinical trial (2021) — Turmeric and curcumin
• 21 Effects of curcumin-piperine co-supplementation on clinical signs, duration, severity, and inflammatory markers in patients with COVID-19: a structured randomised trial (2020) — Turmeric and curcumin
• 22 Prophetic medicine – Nigella sativa (black cumin seeds): a potential herb for COVID-19? (2020) — Black cumin (Nigella sativa)
• 23 Honey and Nigella sativa against COVID-19 in Pakistan (HNS-COVID-PK): a multicentre, placebo-controlled, randomised clinical trial (2023) — Black cumin (Nigella sativa)
• 24 The effect of <i>Nigella sativa</i> and vitamin D3 supplementation on the clinical outcome in COVID-19 patients: a randomised controlled clinical trial (2022) — Black cumin (Nigella sativa)

5. Open Questions

• Humic acid complexes: Which specific viruses are inhibited in humans, and what is the therapeutic dose?
• Gut microbiome: Can antiviral effects be reproducibly demonstrated through targeted microbiome modulation?
• Combination therapies: Are there synergistic effects between compounds with different mechanisms of action (e.g., zinc + quercetin)?
• Long-term effects: How do chronic anti-inflammatory agents (e.g., turmeric) affect immune responses during repeated infections?
• Specificity: Can compounds such as beta-glucans or probiotics be used in a targeted manner against specific viruses, or do they act as non-specific immune stimulants?
• Bioavailability: How can the absorption of poorly soluble compounds (e.g., curcumin) in humans be improved to confirm laboratory findings?

See also the gap list on all compounds. This page is recalculated with each harvest.